DelveInsight’s ‘Acute Respiratory Distress Syndrome Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Acute Respiratory Distress Syndrome therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Respiratory Distress Syndrome pipeline domain.
For Acute Respiratory Distress Syndrome emerging drugs, the Acute Respiratory Distress Syndrome pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MoA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report
- DelveInsight’s Acute respiratory distress syndrome (ARDS) Pipeline report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Acute respiratory distress syndrome pipeline landscape.
- The leading Acute Respiratory Distress Syndrome companies include Athersys Inc., Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, and others are evaluating their lead assets to improve the Acute Respiratory Distress Syndrome treatment landscape.
- Key Acute Respiratory Distress Syndrome pipeline therapies in various stages of development include MultiStem, HCR040, Wharton’s jelly derived Mesenchymal stem cells, TNX-832, Descartes 30, UMC119-06, HLCM051, CUROSURF, BAY1097761, ALT-836, Interferon Beta, and others.
- In March 2023, Tetra Bio-Pharma received up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development project to enable the development of its ARDS-003 oral formulation. Specifically, the funds will be used to optimize the formulation and perform animal non-GLP Pharmacokinetic Studies.
- MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
- Remestemcel-L received Fast Track designation for SARS-COV-2 acute respiratory disease. The US FDA advised Mesoblast for additional clinical study in Covid-19 ARDS in addition to the completed clinical study to support an emergency use authorization (EUA).
- Windtree completed a Phase II study evaluating changes in physiological parameters in Covid-19 patients who are intubated and mechanically ventilated for associated lung injury and ARDS. The study aimed to establish the dosing regimen, tolerability, and functional changes in gas exchange and lung compliance after lucinactant administration. It is awarded Orphan Drug product designation in the US and Europe and Fast Track designation in the US for treating ARDS.
- EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with ARDS. In December 2022, EB05 was granted Fast Track designation from the FDA.
Request a sample and discover the recent breakthroughs happening in the Acute Respiratory Distress Syndrome pipeline landscape @ Acute Respiratory Distress Syndrome Pipeline Outlook
Acute Respiratory Distress Syndrome Overview
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by fluid leakage into the lungs, making breathing difficult or impossible.
Acute respiratory distress syndrome causes are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
Acute respiratory distress syndrome symptoms include shortness of breath, cough, and fever; in some cases, fast heart rates and rapid breathing have also been reported. Occasionally, patients of ARDS experience chest pain, especially during inhalation, and some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. Several risk factors may escalate the risk of ARDS; this involves obesity, alcohol abuse, chemotherapy, low-protein in blood.
Acute respiratory distress syndrome treatment is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management; relatively few treatments are available for ARDS.
Find out more about acute respiratory distress syndrome medication @ New Drug for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome Pipeline Analysis: Drug Profile
MN-166: MediciNova
MN-166 (ibudilast) is a small molecule compound being developed by MediciNova that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). The company recently announced positive top-line results from the Phase II clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing ARDS.
BIO-11006: BioMarck Pharmaceuticals
BioMarck Pharmaceuticals is developing its lead compound BIO-11006 for the treatment of ARDS. Biomarck’s BIO-11006 is a novel, highly soluble, patented 10 amino acid peptide. In April 2020, the company announced positive Phase II results. The drug is ready to enter Phase III for the treatment of ARDS.
Acute Respiratory Distress Syndrome Pipeline Therapies and Key Companies
- EB05: Edesa Biotech/Light Chain Bio
- DB-001: Direct Biologics
- BIO-11006: BioMarck Pharmaceuticals
- Lucinactant: Windtree Therapeutics
- MultiStem (HLCM051): Athersys/Healios
- Zavegepant (BHV-3500): Biohaven Pharmaceutical
- Metablok (LSALT peptide): Arch Biopartners
Learn more about the novel and emerging Acute Respiratory Distress Syndrome pipeline therapies @ Acute Respiratory Distress Syndrome Clinical Trials
Acute Respiratory Distress Syndrome Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Subcutaneous
- Intramuscular
- Intravenous
- By Molecule Type
- Monoclonal antibodies
- Stem cell therapies
- Immunoproteins
- Peptides
- Proteins
Scope of the Acute Respiratory Distress Syndrome Pipeline Report
- Coverage: Global
- Key Acute Respiratory Distress Syndrome Companies: Athersys Inc., Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, and others.
- Key Acute Respiratory Distress Syndrome Pipeline Therapies: MultiStem, HCR040, Wharton’s jelly derived Mesenchymal stem cells, TNX-832, Descartes 30, UMC119-06, HLCM051, CUROSURF, BAY1097761, ALT-836, Interferon Beta, and others.
Dive deep into rich insights for drugs used for Acute Respiratory Distress Syndrome treatment; visit @ Acute Respiratory Distress Syndrome Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Acute Respiratory Distress Syndrome Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Acute Respiratory Distress Syndrome Pipeline Therapeutics |
| 6. | Acute Respiratory Distress Syndrome Pipeline: Late Stage Products (Phase III) |
| 7. | Acute Respiratory Distress Syndrome Pipeline: Late Stage Products (Phase III) |
| 8. | Acute Respiratory Distress Syndrome Pipeline: Mid Stage Products (Phase II) |
| 9. | Acute Respiratory Distress Syndrome Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Acute Respiratory Distress Syndrome therapy in the pipeline, reach out @ Acute Respiratory Distress Syndrome Medication
Related Reports
Acute Respiratory Distress Syndrome Market
Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Acute Respiratory Distress Syndrome companies involved such as BioXcellerator, Altor BioScience, Cartesian Therapeutics, among others.
Acute Respiratory Distress Syndrome Epidemiology Forecast
Acute Respiratory Distress Syndrome Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted Acute Respiratory Distress Syndrome epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Pulmonary Fibrosis Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Pulmonary Fibrosis companies involved, such as BioXcellerator, Altor BioScience, Cartesian Therapeutics, among others.
Asthma Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Asthma companies involved, such as Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, and others.
Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Pulmonary Fibrosis companies involved, such as BioXcellerator, Altor BioScience, Cartesian Therapeutics, among others.
Asthma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Asthma companies involved, such as Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, among others.
Other Trending Reports
CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Latest Reports
- Menorrhalgia Market
- Complicated Intra-Abdominal Infections market
- Bronchial Spasm Market
- Acute Radiation Syndrome Market
- Age Related Vision Dysfunction Market
- Cerebral Aneurysm Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Kaveri Bisht
info@delveinsight.com
+1(919)321-6187